CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hu, Shimin, Xu-Monette, Zijun Y., Balasubramanyam, Aarthi, Manyam, Ganiraju C., Visco, Carlo, Tzankov, Alexander, Liu, Wei-min, Miranda, Roberto N., Zhang, Li, Montes-Moreno, Santiago, Dybkær, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W. L., Han van Krieken, J., Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J. M., Zhao, Xiaoying, Winter, Jane N., Zhang, Mingzhi, Li, Ling, Møller, Michael B., Piris, Miguel A., Li, Yong, Go, Ronald S., Wu, Lin, Medeiros, L. Jeffrey, Young, Ken H.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2013
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3700465/
https://ncbi.nlm.nih.gov/pubmed/23343832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-10-461848
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars